Publication details

The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study

Authors

ZELINKA Jiří BLAHÁK Jiří PEŘINA Vojtěch PACASOVÁ Rita TREGLEROVÁ Jana BULIK Oliver

Year of publication 2021
Type Article in Periodical
Magazine / Source Biomedical Papers
MU Faculty or unit

Faculty of Medicine

Citation
Web https://biomed.papers.upol.cz/artkey/bio-202103-0013_the-use-of-platelet-rich-fibrin-in-the-surgical-treatment-of-medication-related-osteonecrosis-of-the-jaw-40-pa.php?back=%2Fsearch.php%3Fquery%3DZelinka%2Bin%253Aauth%2Bname%2Bkey%2Babstr%26sfrom%3D0%26
Doi http://dx.doi.org/10.5507/bp.2020.023
Keywords medication related osteonecrosis of the jawplatelet rich fibrinsurgical treatment
Description Medication-related osteonecrosis of the jaw (MRONJ) is defined as exposed bone in the maxillofacial region persisting for more than eight weeks in patients who are or were treated with antiresorptive or antiangiogenic agents and had no radiation therapy to the craniofacial region or obvious metastatic disease of the jaws. It is a recognised side effect of antiresorptive or antiangiogenic medication. To date, there is no specific gold standard treatment for MRONJ cases. The aim of this study was to evaluate the successful rate of surgical treatment with adjuvant local application of platelet rich fibrin.

You are running an old browser version. We recommend updating your browser to its latest version.

More info